Tuesday, November 14, 2023
The Karmanos Cancer Institute, affiliated with McLaren Health Care and renowned as Michigan's primary cancer care provider, is poised to be at the forefront of introducing the recently FDA-approved TheraBionic P1 device for treating advanced hepatocellular carcinoma (HCC). HCC, constituting around 90% of liver cancers, typically carries a survival prognosis of 6 to 20 months. The innovative TheraBionic P1 device, sanctioned for patients aged 18 and above who have not responded to initial treatments, offers a non-invasive at-home solution.
Emitting low-frequency radio-frequency electromagnetic fields, the device selectively hampers tumor cell growth while preserving healthy tissue integrity. This groundbreaking device is expected to bring transformative benefits to physicians nationwide, providing a means to extend the lives of individuals grappling with this formidable disease. Administered through three daily one-hour sessions using a portable hand-held device and a tongue-placed antenna, the TheraBionic P1 device introduces a promising alternative for patients with limited treatment options due to compromised liver function.
The Institute expresses enthusiasm for delivering an effective, user-friendly solution that aligns with the most advanced treatments available for advanced hepatocellular carcinoma. Moreover, ongoing clinical trials are actively investigating the TheraBionic P1 device's effectiveness in treating various other cancers, including breast, brain, ovarian, gallbladder, pancreatic, and prostate cancers.
Source: prnewswire.com
